BACKGROUND: Bacterial biofilm formation on hemodialysis tunneled cuffed catheters is under-recognized. We studied biofilm characteristics in patients with and without catheter-related bloodstream infection, accounting for catheter locking solution (citrate 4% or heparin 1:1,000). STUDY DESIGN: Prospective observational study. SETTING & PARTICIPANTS: 30 HD patients for whom the tunneled cuffed catheter was removed for either noninfectious reasons (n = 19) or bacteremia (n = 11). PREDICTORS: Bacteremia and catheter locking solution. OUTCOMES & MEASUREMENTS: Bacteria density in the biofilm, catheter luminal surface covered by biofilm, biofilm thickness, and exopolysaccharide content. RESULTS: Biofilm was present in all catheters. Overall, bacteria density, catheter surface coverage, biofilm thickness, and exopolysaccharide content were significantly higher in catheters from patients with bacteremia (5.3 [95% CI, 3.4-7.2] colony-forming unit [CFU]/mL; 47% [95% CI, 34%-60%]; 41 [95% CI, 26-55] μm; and 29.4% [95% CI, 20.1%-38.6%], respectively) than from patients without bacteremia (3.7 [95% CI, 3.6-3.8] CFU/mL; 17% [95% CI, 16%-19%]; 8.6 [95% CI, 7.3-9.8] μm; and 5.3% [95% CI, 3.7%-6.8%], respectively). However, all biofilm parameters were lower in catheters from patients with bacteremia when citrate was used as locking agent. Furthermore, bacteria density (0.08 [95% CI, 0.02-0.13] CFU/mL/3 cm), biofilm thickness (1.4 [95% CI, 0.8-2.1] μm/3 cm), and surface coverage (2.2% [95% CI, 1.8%-2.7%]/3 cm) decreased across the length of the catheter from tip to hub. LIMITATIONS: Observational study design, small numbers of patients, use of prevalent catheters. CONCLUSION: Biofilms are present in all tunneled cuffed catheters. However, the extent of the biofilm varied by the presence of bacteremia and type of locking solution. This method could be used to explore preventative measures.
BACKGROUND: Bacterial biofilm formation on hemodialysis tunneled cuffed catheters is under-recognized. We studied biofilm characteristics in patients with and without catheter-related bloodstream infection, accounting for catheter locking solution (citrate 4% or heparin 1:1,000). STUDY DESIGN: Prospective observational study. SETTING & PARTICIPANTS: 30 HDpatients for whom the tunneled cuffed catheter was removed for either noninfectious reasons (n = 19) or bacteremia (n = 11). PREDICTORS: Bacteremia and catheter locking solution. OUTCOMES & MEASUREMENTS: Bacteria density in the biofilm, catheter luminal surface covered by biofilm, biofilm thickness, and exopolysaccharide content. RESULTS: Biofilm was present in all catheters. Overall, bacteria density, catheter surface coverage, biofilm thickness, and exopolysaccharide content were significantly higher in catheters from patients with bacteremia (5.3 [95% CI, 3.4-7.2] colony-forming unit [CFU]/mL; 47% [95% CI, 34%-60%]; 41 [95% CI, 26-55] μm; and 29.4% [95% CI, 20.1%-38.6%], respectively) than from patients without bacteremia (3.7 [95% CI, 3.6-3.8] CFU/mL; 17% [95% CI, 16%-19%]; 8.6 [95% CI, 7.3-9.8] μm; and 5.3% [95% CI, 3.7%-6.8%], respectively). However, all biofilm parameters were lower in catheters from patients with bacteremia when citrate was used as locking agent. Furthermore, bacteria density (0.08 [95% CI, 0.02-0.13] CFU/mL/3 cm), biofilm thickness (1.4 [95% CI, 0.8-2.1] μm/3 cm), and surface coverage (2.2% [95% CI, 1.8%-2.7%]/3 cm) decreased across the length of the catheter from tip to hub. LIMITATIONS: Observational study design, small numbers of patients, use of prevalent catheters. CONCLUSION: Biofilms are present in all tunneled cuffed catheters. However, the extent of the biofilm varied by the presence of bacteremia and type of locking solution. This method could be used to explore preventative measures.
Authors: Pietro Ravani; Suetonia C Palmer; Matthew J Oliver; Robert R Quinn; Jennifer M MacRae; Davina J Tai; Neesh I Pannu; Chandra Thomas; Brenda R Hemmelgarn; Jonathan C Craig; Braden Manns; Marcello Tonelli; Giovanni F M Strippoli; Matthew T James Journal: J Am Soc Nephrol Date: 2013-02-21 Impact factor: 10.121
Authors: Pietro Ravani; Robert Quinn; Matthew Oliver; Bruce Robinson; Ronald Pisoni; Neesh Pannu; Jennifer MacRae; Braden Manns; Brenda Hemmelgarn; Matthew James; Marcello Tonelli; Brenda Gillespie Journal: Clin J Am Soc Nephrol Date: 2017-05-18 Impact factor: 8.237
Authors: Brenda R Hemmelgarn; Braden J Manns; Steven D Soroka; Adeera Levin; Jennifer MacRae; Karthik Tennankore; Jo-Anne S Wilson; Robert G Weaver; Pietro Ravani; Robert R Quinn; Marcello Tonelli; Mercedeh Kiaii; Paula Mossop; Nairne Scott-Douglas Journal: Clin J Am Soc Nephrol Date: 2018-01-15 Impact factor: 8.237
Authors: Pietro Ravani; Brenda W Gillespie; Robert Ross Quinn; Jennifer MacRae; Braden Manns; David Mendelssohn; Marcello Tonelli; Brenda Hemmelgarn; Matthew James; Neesh Pannu; Bruce M Robinson; Xin Zhang; Ronald Pisoni Journal: J Am Soc Nephrol Date: 2013-07-11 Impact factor: 10.121
Authors: Edward Clark; Joanne Kappel; Jennifer MacRae; Christine Dipchand; Swapnil Hiremath; Mercedeh Kiaii; Charmaine Lok; Louise Moist; Matthew Oliver; Lisa M Miller Journal: Can J Kidney Health Dis Date: 2016-09-27
Authors: Kylie Martin; Yves S Poy Lorenzo; Po Yee Mia Leung; Sheri Chung; Emmet O'flaherty; Nuala Barker; Francesco Ierino Journal: Open Forum Infect Dis Date: 2020-04-11 Impact factor: 3.835